Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: The Tokyo Children's Cancer Study Group Study L99-15

Haematologica

Volumn 93, Issue 8, 2008, Pages 1155-1160

  Manabe, Atsushi ^a   Ohara, Akira ^b   Hasegawa, Daisuke ^a   Koh, Katsuyoshi ^c   Saito, Tomohiro ^d   Kiyokawa, Nobutaka ^d   Kikuchi, Akira ^e   Takahashi, Hiroyuki ^f   Ikuta, Koichiro ^g   Hayashi, Yasuhide ^h   Hanada, Ryoji ^e   Tsuchida, Masahiro ⁱ  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^f Saiseikai Yokohama City Nanbu Hospital   (Japan)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

^h Gunma Children's Medical Center   (Japan)

ⁱ Ibaraki Children's Hospital   (Japan)

Author keywords

Children; Clearance of blasts; Lymphoblastic leukemia; Steroid response

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL LINEAGE; CHILD; CHROMOSOME; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INTENSIVE CARE; JAPAN; LEUKEMIA CELL; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TREATMENT FAILURE;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; RETROSPECTIVE STUDIES; TOKYO;

EID: 48749083578     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12365     Document Type: Article

References (22)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia: current status and future perspectives. Lancet Oncol 2001;2:597-607.
2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
3. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Paediatr 1987;199:151-60.
4. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995;86:1292-5.
5. Lilleyman JS, Gibson BE, Stevens RF, Will AM, Hann IM, Richards SM, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin: the Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1997;97:603-6.
6. +) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92:2730-41.
7. Dordelmann M, Reiter A, Borkhardt A, Ludwig WD, Gotz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94:1209-17.
8. Reiter A, M Schrappe, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
9. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Benoit Y, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-9.
10. Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Mucombining double vertical line aboveenster protocol II. Blood 2002;100:420-6.
11. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099-111.
12. Manabe A, Tsuchida M, Hanada R, Ikuta K, Toyoda Y, Okimoto Y, et al. Delay of the diagnostic lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia who undergo routine corticosteroid testing: Tokyo Children's Cancer Study Group study L89-12. J Clin Oncol 2001;19:3182-7.
13. Manabe A, Ohara A, Ikuta K, Hanada R, Yabe H, Kinoshita A, et al. The effect of early high dose Ara-C in children with high-risk acute lymphoblastic leukemia (ALL): Tokyo Children's Cancer Study Group (TCCSG) study L99-15. Blood 2005;106:255a. [abstract]
14. Borowitz MJ, Devidas M, Bowman WP, Carroll WL, Chen IM, Harvey R, et al. Prognostic significance of minimal residual disease (MRD) in childhood B-precursor ALL and its relation to other risk factors. A Children's Oncology Group (COG) study. Blood 2006;108:69a[abstract].
15. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.
16. Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006;108:1050-7.
17. Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ, et al. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007;109:3929-35.
18. Holleman A, den Boer ML, de Menezes RX, Cheok MH, Cheng C, Kazemier KM, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006;107:769-76.
19. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000;14:2205-22.
20. Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr 2001;213:169-74.
21. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18:1508-16.
22. Pui CH, Aur RJ, Bowman WP, Dahl GV, Dodge RK, George SL, et al. Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia. Cancer Res 1984;44:3593-8.